乳酸菌菌 (Lacticaseibacillus rhamnosus) IDCC 3201对便秘的刺激性肠综合征的影响:一个随机,双盲和安慰剂对照的试验
Hyeji Kwon1, Eoun Ho Nam2,3, Hayoung Kim4
1Immunology Laboratory, Cancer Genomic Research Institute, Seoul Song Do Colorectal Hospital, Seoul, 04597, Republic of Korea.
Scientific reports
|September 27, 2024
概括
在一项随机试验中,Lacticaseibacillus rhamnosus IDCC 3201 (RH 3201) 显著改善了便秘主导的刺激性肠综合征 (IBS-C) 症状. 益生菌疗法增强了肠道微生物群和代谢物,为IBS-C患者提供了潜在的新疗法.
科学领域:
- 胃肠病学 胃肠病学
- 微生物组研究的研究.
- 临床营养学 临床营养学
背景情况:
- 刺激性肠综合征 (IBS) 是一种慢性胃肠道疾病,影响患者的生活质量.
- 便秘性刺激性肠综合征 (IBS-C) 是一种由特定的肠道症状和不适所特征的亚型.
- 目前对IBS-C的管理策略存在局限性,需要新的治疗方法.
研究的目的:
- 评估Lacticaseibacillus rhamnosus IDCC 3201 (RH 3201) 在缓解IBS-C.的症状方面的疗效.
- 研究RH 3201对IBS-C患者便微生物组合的影响.
- 探索肠道代谢物和临床症状改善之间的潜在相关性.
主要方法:
- 一个随机,双盲,安慰剂对照试验,涉及30名IBS-C受试者.
- 参与者接受了RH 3201或安慰剂8周.
- 分析了肠道活动,IBS症状,便微生物组和代谢组.
主要成果:
- RH 3201显著改善了肠道运动规律性和便秘相关的不适.
- 腹部膨胀的严重程度和频率下降,在益生菌组中改善了肠道习惯的满意度.
- 观察到细菌细胞菌和菌菌的丰度增加,以及特定的代谢物变化.
结论:
- 在改善IBS-C症状方面,乳酸菌cillus rhamnosus IDCC 3201显示出显著的有效性.
- 益生菌可以通过调节肠道微生物群和相关代谢途径来发挥其作用.
- RH 3201代表了一种有前途的治疗选择,用于管理IBS-C.
相关概念视频
01:21Drugs for Treatment of Constipation-Predominant IBS
140
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
140
01:17Drugs for Treatment of Diarrhea-Predominant IBS
151
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
151
01:17Irritable Bowel Syndrome I: Introduction
254
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
254
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
174
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
174
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
146
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
146
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
323
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
323